Navigation Links
Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
Date:1/6/2009

Lead candidate on track for IND submission first half of 2009.

SAN DIEGO, Jan. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced AM211, Amira's internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.

AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor for prostaglandin (PG) D2 and, in humans, is implicated in Th2-dependent allergic inflammation. Recent studies have shown that a DP2 antagonist has the potential to be an oral treatment for asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.

"Our pre-clinical studies demonstrate that a low dose of AM211 is effective in several inflammatory/allergic models," said Peppi Prasit, PhD, Chief Scientific Officer, Amira. "Based on the pharmacokinetics and pharmacodynamics in preclinical models and its safety profile, we believe that AM211 has the potential to be an exciting next generation, once a day oral medication for respiratory diseases including COPD. In addition, we have a structurally distinct backup compound, AM461, about to enter GLP toxicity studies."

"Amira is establishing a track record of rapid and efficient discovery and early drug development. For the second time in as many programs, Amira is on track to enter human studies within two years from program start," said Bob Baltera, Amira's Chief Executive Officer. "These are exciting times at Amira as our team continues to demonstrate world-class capabilities in drug discovery and development."

About Amira

Founde
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Amira Pharmaceuticals Appoints First Vice President of Development
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. American Asthma Foundation Announces Breakthrough Discovery
7. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
8. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
9. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
10. FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
11. B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... being revitalized and expanded through a U.S.-funded effort ... Internet access and providing cutting-edge skills labs and ... publication by participants of the $130 million Medical ... detailed progress being made at the African institutions. ... today by the journal Academic Medicine . ...
(Date:7/30/2014)... Good Neighbor Community Services announced that ... of Innovations with Ed Begley Jr, airing later ... times TBA. , In this segment, viewers will ... to redefine the traditional approach to serving the ... passion, innovation, determination, excellence, and collaboration, Good Community ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- It can happen in ... television, dresser or computer monitor and gets critically injured when ... a young child should look around their homes and imagine ... child. Imagining it is better than it becoming a reality," ... Physicians, said in a college news release. Between 2009 ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... 2014 Visitors to our region recognize ... to ensure its protection. Bob Kiesendahl, one of the ... the Delaware Highlands Conservancy for donations collected through participation ... donations add up fast, as visitors welcome the opportunity ... River Region. , The Kiesendahl family has owned Woodloch ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2
... 30 The American Lung,Association of Iowa will host a week ... 2008. The camp is open for all children with,asthma from ages ... for kids with asthma to spend a week doing,things all other ... Lung Association, "It is a chance for kids to learn that,having ...
... PORTLAND, Ore. Men with a certain type of ... new chemotherapy drug, Sagopilone, plus prednisone in an international ... Institute researchers. , The research involved men with ... has spread beyond the prostate and is not longer ...
... Dynamic Student Services ... ... ) the architectural, planning and interiors,firm, has transformed a shuttered South ... Golden Gate,University (GGU). As the new "front door" for the downtown ...
... masses in the colon is the same for average-risk patients ... who are 50 to 59 years of age, reports a ... the American Gastroenterological Association (AGA) Institute. , Currently, standard ... cancer based on the increasing incidence of colon cancer at ...
... learn CPR/AED, WASHINGTON, May 30 Sudden ... people in this country every year.,Sadly, an astonishing ... arrest,die before reaching a hospital. If ordinary people ... Automated External,Defibrillator (AED), instead of just waiting for ...
... looks hopeful, but it,s still too early to make ... 30 (HealthDay News) -- An antioxidant found in green ... a toxic protein associated with Alzheimer,s and Parkinson,s disease, ... seen in the brains of Alzheimer,s patients and appears ...
Cached Medicine News:Health News:OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer 2Health News:Golden Gate University Opens New Student Services Center 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 3Health News:National CPR/AED Awareness Week 2Health News:Green Tea Antioxidant May Help Prevent Alzheimer's 2Health News:Green Tea Antioxidant May Help Prevent Alzheimer's 3
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
(Date:7/30/2014)... and NEW YORK , July 30, ... developer of new products for oncology supportive care, announced ... , has been featured in an article on OncLive.com ... in Head and Neck Cancers."  Dr. Steve Sonis ... on the growing demand seen in the oncology community ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... 12, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX), today ... efforts will be presented at the 98th,Annual ... Research,April 14-18, 2007 in Los Angeles, CA., ... Therapy", Heilbut, et.al. (Abstract #1410) will be ...
... Oncology Portfolio, SOUTH SAN FRANCISCO, Calif., April ... the presentation of four research projects aimed ... as,potential therapeutics for certain types of cancers ... presentations during,poster sessions from April 16th to ...
Cached Medicine Technology:CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting 2CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting 3Rigel to Present New Research Programs at AACR Meeting 2Rigel to Present New Research Programs at AACR Meeting 3Rigel to Present New Research Programs at AACR Meeting 4Rigel to Present New Research Programs at AACR Meeting 5
1.0 mm diameter head, 0.75 mm deep bite....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Medicine Products: